Amneal Pharmaceuticals (AMRX) Retained Earnings (2017 - 2026)

Amneal Pharmaceuticals' Retained Earnings history runs 10 years deep, the most recent figure standing at -$472.7 million for Q1 2026.

• In Q1 2026, Retained Earnings rose 20.53% year-over-year to -$472.7 million; the TTM figure through Mar 2026 stood at -$472.7 million (up 20.53% YoY), while the FY2025 annual figure was -$535.0 million, down 716.68% from the prior year.
• Retained Earnings was -$472.7 million for Q1 2026 at Amneal Pharmaceuticals, up from -$535.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $12.5 million in Q3 2022 to a low of -$594.9 million in Q1 2025.
• Historically, Retained Earnings has averaged -$173.7 million across 5 years, with a median of -$30.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings jumped 1178.51% in 2023, then slumped 14971.7% in 2024.
• A 5-year view of Retained Earnings shows it stood at $9.9 million in 2022, then sank by 5031.84% to -$490.2 million in 2023, then jumped by 86.64% to -$65.5 million in 2024, then plunged by 716.68% to -$535.0 million in 2025, then rose by 11.64% to -$472.7 million in 2026.
• The last three Retained Earnings figures came in at -$472.7 million (Q1 2026), -$535.0 million (Q4 2025), and -$105.9 million (Q3 2025), per Business Quant data.